Claims
- 1. An isolated nucleic acid comprising DNA having at least 95% sequence identity to (a) a DNA molecule encoding a PRO364 polypeptide comprising the sequence of amino acid residues 1 to 241 of FIG. 2A (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a).
- 2. The nucleic acid of claim 1, wherein said DNA comprises the nucleotide sequence of SEQ ID NO:1 or its complement.
- 3. The nucleic acid of claim 1, wherein said DNA comprises nucleotides 121-843 of the nucleotide sequence of SEQ ID NO:1.
- 4. An isolated nucleic acid comprising DNA having at least 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the cDNA in ATCC Deposit No. 209436 (DNA47365-1206), or (b) the complement of the DNA molecule of (a).
- 5. The nucleic acid of claim 4 which comprises a DNA molecule encoding the same mature polypeptide encoded by the cDNA in ATCC Deposit No. 209436 (DNA47365-1206).
- 6. An isolated nucleic acid comprising DNA having at least 95% sequence identity to (a) a DNA molecule encoding a PRO364 polypeptide comprising the sequence of amino acid residues 1 to X of FIG. 2A (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a), wherein X is any one of amino acid residues 157-167 of FIG. 2A (SEQ ID NO:3).
- 7. An isolated nucleic acid comprising DNA having at least 95% sequence identity to (a) a DNA molecule encoding a PRO364 polypeptide comprising the sequence of amino acid residues 26 to 241 of FIG. 2A (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a).
- 8. An isolated nucleic acid comprising DNA having at least 950W sequence identity to (a) a DNA molecule encoding a PRO364 polypeptide comprising the sequence of amino acid residues 26 to X of FIG. 2A (SEQ ID NO:3), or (b) the complement of the DNA molecule of (a), wherein X is any one of amino acid residues 157-167 of FIG. 2 (SEQ ID NO:3).
- 9. An isolated nucleic acid comprising DNA from the group consisting of:
a) a DNA having at least 800 sequence identity to a DNA sequence encoding a PRO364 polypeptide comprising amino acid residues 26 to 241 of FIG. 2A (SEQ ID NO:3); b) a DNA sequence that hybridizes under stringent conditions to a DNA of a); c) a DNA sequence that, due to the degeneracy of the genetic code, encodes a PRO364 polypeptide of a); and d) DNA complementary to the DNA of a), b), or c).
- 10. A vector comprising the nucleic acid of any one of claims 1 to 9.
- 11. The vector of claim 10 operably linked to control sequences recognized by a host cell transformed with the vector.
- 12. A host cell comprising the vector of claim 10.
- 13. The host cell of claim 12, wherein said cell is a CHO cell.
- 14. The host cell of claim 12, wherein said cell is an E. coli.
- 15. The host cell of claim 12, wherein said cell is a yeast cell.
- 16. A process for producing a PRO364 polypeptide comprising culturing the host cell of claim 12 under conditions suitable for expression of said PRO364 polypeptide and recovering said PRO364 polypeptide from the cell culture.
- 17. An isolated PRO364 polypeptide comprising amino acid residues 1 to 241 of FIG. 2A (SEQ ID NO:3).
- 18. An isolated PRO364 polypeptide encoded by the cDNA insert of the vector deposited as ATCC Accession No. 209436 (DNA47365-1206).
- 19. An isolated PRO364 polypeptide comprising amino acid residues 1 to X of FIG. 2A (SEQ ID NO:3), wherein X is any one of amino acid residues 157-167 of FIG. 2A (SEQ ID NO:3).
- 20. An isolated PRO364 polypeptide comprising amino acid residues 26 to 241 of FIG. 2A (SEQ ID NO:3).
- 21. An isolated PRO364 polypeptide comprising amino acid residues 26 to X of FIG. 2A (SEQ ID NO:3), wherein X is any one of amino acid residues 157-167 of FIG. 2A (SEQ ID NO:3).
- 22. An isolated PRO364 polypeptide comprising a polypeptide selected from the group consisting of:
a) a PRO364 polypeptide comprising amino acid residues 26 to X of FIG. 2A (SEQ ID NO:3), wherein X is any one of amino acid residues 157-167 of FIG. 2A (SEQ ID NO:3); and b) a fragment of a), wherein said fragment is a biologically active polypeptide.
- 23. A chimeric molecule comprising a PRO364 polypeptide fused to a heterologous amino acid sequence.
- 24. The chimeric molecule of claim 23, wherein said heterologous amino acid sequence is an epitope tag sequence.
- 25. The chimeric molecule of claim 23, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.
- 26. An antibody which specifically binds to a PRO364 polypeptide.
- 27. The antibody of claim 26, wherein said antibody is a monoclonal antibody.
- 28. A composition comprising an isolated PRO364 polypeptide of claims 17, 18, 19, 20, 21, or 22 and a carrier.
- 29. The composition of claim 28 wherein said carrier is a pharmaceutically-acceptable carrier.
- 30. A method of modulating apoptosis in mammalian cells, comprising exposing said cells to an effective amount of PRO364 polypeptide.
- 31. A method of modulating NF-κB activation in mammalian cells, comprising exposing said cells to an effective amount of PRO364 polypeptide.
- 32. A method of modulating a proinflammatory or autoimmune response in mammalian cells, comprising exposing said cells to an effective amount of PRO364 polypeptide.
RELATED APPLICATIONS
[0001] This is a non-provisional application filed under 37 CFR 1.53(b) claiming priority under Section 119(e) to provisional application No. 60/074,087 filed Feb. 9, 1998, the contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60074087 |
Feb 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09247225 |
Feb 1999 |
US |
Child |
10116378 |
Apr 2002 |
US |